Dimerix Limited · ASX:DXB
Dimerix — Shareholder Meeting (November 2014)
33 slides from Dimerix's shareholder meeting presentation, November 2014

Slide 1: Clinical phase biotech company with development pipeline
Clinical phase biotech company with development pipeline AGM - November 2014

Slide 2: Disclaimer
Disclaimer This presentation prepared by Dimerix Bioscience Pty Ltd, in the process of converting to Dimerix Biosciences Limited, ("Company" or “Dimerix”) does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitati

Slide 3: Dimerix Overview
Dimerix Overview Lead program: DMX200 – PII asset for treatment of Chronic Kidney Disease − Human PoC study commenced AusBn Hospital (Funded) − Development program focused on fast-‐track to IND and orphan designaBon − CombinaBon of 2 drugs with extensive human data − Patent applicaBons in NaBonal p

Slide 4: Dimerix Programs
Dimerix Programs Ethics and site iniBaBon complete at AusBn Hospital Phase II ready clinical program, mul5ple pipeline opportuni5es, plus top 10 pharma engagement for development platform

Slide 5: Team
Dimerix

Slide 6: Executive Board & Management
Executive Board & Management Exec. Chairman: • Co-founder of Dimerix and iCeutica (acquired in 2011 and now Dr James Williams with 2 FDA drug approvals) BSc(Hons), PhD, MBA • Co-founder of Yuuwa Capital ($40M venture capital fund) • Former Managing Director of Resonance Health and Argus Biomedical (

Slide 7: Non-Executive Directors
Non-Executive Directors Director: • Current – Medical Director INC Research Dr David Fuller • 20+ years international experience commercialising BPharm, MBBS therapeutic products • Former Executive Director Genzyme UK and Chief Medical Officer of Arana Therapeutics (valued at >$300 million when take

Slide 8: Key Advisors
Key Advisors Chief Scientific Adviser • Inventor Dimerix technology A/Prof Kevin Pfleger • Head Molecular Endocrinology and Pharmacology at the MA (Camb.) PhD Harry Perkins Institute of Medical Research (Edin.) • Australian Research Council Future Fellow • Recipient of Young Scientist of the Year Aw

Slide 9: GPCR-Heteromer Identification Technology
GPCR-Heteromer Identification Technology A powerful discovery platform

Slide 10: GPCR – From a signalling pathway to a profile
GPCR – From a signalling pathway to a profile GPCR monomer/homomer signaling GPCR heteromer signaling and / or and / Different G-protein G-protein or β-arrestin Different mediated mediated mediated G-protein- β-arrestin pathways pathways pathways mediated mediated pathways pathways Knowledge and opt

Slide 11: GPCR-HIT: CCR2/Rluc8 and AT1R recruitment of β-arrestin2
GPCR-HIT:CCR2/Rluc8 and AT1R recruitment of β-arrestin2 CCR2-‐Rluc8 AT1R Angiotensin II β-arrestin Rluc8 Rluc8 Venus β-arrestin BRET Venus A signal is only generated when the receptors are in functional proximity

Slide 12: Identification of CCR2 and heteromer
Identification of CCR2 and heteromer More than additive effect of co-treating with agonists for both receptors

Slide 13: CCR2/AT1R heteromer: In vitro antagonist studies
CCR2/AT1R heteromer: In vitro antagonist studies Require treatment with both CCR2 antagonist (RS504393) and AT1R antagonist (Irbesartan) to reduce signal from dual CCL2 and AngII stimulation. Dimerix sought to test this in vivo

Slide 14: DMX200 Clinical Program & Market Need CKD
DMX200 Clinical Program & Market Need CKD

Slide 15: DMX200: Phase II Clinical Trial
DMX200: Phase II Clinical Trial • Treatment of Proteinuria in CKD paBents • Study design: Fixed dose combinaBon of Irbesartan + Propagermanium • Enrollment: Up to 60 paBents in two Parts • Part A: Dose escalation – Up to 5 doses x 1 month, then 3 months at maximal dose • Part B: “Best dose” combinaB

Slide 16: Chronic Kidney Disease (CKD) US patients
Chronic Kidney Disease (CKD) 26 million US patients: 8.5m patients at or beyond Stage 3 Stage Kidney Function Prevalence 1 Normal kidney function but altered urine findings, structural abnormalities or genetic traits 2 Mildly reduced kidney function, and other findings point to kidney disease 3 Mode

Slide 17: Causes of CKD: segmented market
Causes of CKD: segmented market = different regulatory and reimbursement pathways Disease Example Prevalence Diabetic Kidney Diabetes Type 1, Diabetes Type 2 34% Disease Non-diabetic Glomerular Diseases 24% Kidney - Primary (unknown), AutoImmune, Infection, Drugs Disease Vascular Diseases 14% - Hype

Slide 18: Chronic Kidney Disease: Nephrotic Syndrome
Chronic Kidney Disease: Nephrotic Syndrome • Non-specific disorder where kidneys are damaged; characterised by proteinuria; may also have hypoalbuminemia, hyperlipidemia and edema. • Gold standard diagnosis of nephrotic syndrome is 24 hour urine protein measurement (proteinuria) • Regulatory pathway

Slide 19: Limited Competition for Nephrotic Syndrome
Limited Competition for Nephrotic Syndrome: Questcor – mechanism of action not fully understood Steroids ACTHAr InjecBble Gel Company MulBple Questcor Naturally occurring adrenocorBcotrophic Mechanism Steroid hormone (ACTH) analogue Side effects Multiple –steroid effects on growth, adrenal gland, ot

Slide 20: Competition / Comparators
Competition / Comparators Dimerix

Slide 21: Questcor: Acquired for $5.6 billion
Questcor: Acquired for $5.6 billion (August 2014) • Acthar gel (injection only). • Acthar is a generic adrenocorticotrophic hormone (ACTH) analogue, or steroid, shown to have advantages where paBents are otherwise steroid resistant or cannot tolerate steroids. Long term steroid treatments are not fa

Slide 22: Chemocentryx: Mkt Cap US$203m
Chemocentryx: Mkt Cap US$203m (NASDAQ Nov 2014) • BiopharmaceuBcal company targeting chemokine receptor targets. • Lead program CCX140 targeting chemokine CCR2 receptor in two Phase II clinical trials for diabetic nephropathy. • Second generation compound in Phase 1 clinical trial for other renal di

Slide 23: Fibrotech: Private Australian company
Fibrotech: Private Australian company • VC backed company recently announced to be acquired by Shire PharmaceuBcals • US$75 million upfront consideraBon, plus undisclosed milestones • Fibrotech program in Phase 1b for diabeBc nephropathy • Shire has announced it will target orphan FSGS in first insta

Slide 24: Comparable NASDAQ GPCR Platform Companies
Comparable NASDAQ GPCR Platform Companies Trevena Inc Receptos Inc IPO 5 Feb 2014 14 Jan 2014 Market Cap (Raise) ~$144M ($65m) $3.26B ($117m) (November 2014) Clinical Assets 1xPhase II; 1xPhase III; 1xPhase I 1xPhase II; 1xPhase I PlaNorm Knowhow around GPCR Structure based discovery Biased Ligands

Slide 25: Capital Structure & Finance
Capital Structure & Finance Dimerix

Slide 26: Cap Table
Cap Table Shareholders Ordinary % Holding Peter Meurs 23,939,126 32.8 Pre-‐IPO 9,375,000 12.9 Top up to seed* 5,625,000 7.7 SRV Custodians Pty Ltd 7,390,496 10.1 Yodambao Pty Ltd 7,056,276 9.7 Nullaki Services Pty Ltd aN Anvil Bay Trust 3,495,203 4.8 Toroha Pty Ltd aN White Family Trust 2,949,100 4

Slide 27: Development timeline and Financing
Development timeline and Financing

Slide 28: Further Information
Further Information James Williams, Chairman Corporate Office: +61 409 050 519 L2/25 Flinders Lane, Melbourne, VIC 3000 james@dimerix.com Australia Ph: +61 409 050 519 Dimerix Bioscience Ltd Fax: +61 8 9355 5694 ACN 112 223 417 www.dimerix.com

Slide 29: Regulatory Approach
Regulatory Approach Dimerix

Slide 30: Regulatory path for orphan indication
Regulatory path for orphan indication - small numbers and approx. 6 months duration Treatment of Proteinuria in Membranous Nephropathy Patients Nephrotic Syndrome Study design: Regulatory -‐ 0.5mL injections 5/week vs placebo injection 5/week Approval Path -‐ 1.0mL injections 2/week vs placebo inj

Slide 31: Core Intellectual Property
Core Intellectual Property Combination Therapy: PCT Number: AU2012/000014 International Filing Date: 11 January 2012 Status: National Phase entered Applicant: Dimerix Bioscience Pty Ltd Inventors: PFLEGER, Kevin Donald George; MCCALL, Elizabeth; WILLIAMS, James Applications: Combinations of drugs fo

Slide 32: Example: revenue impact of orphan designations
Example: revenue impact of “orphan designations” Source: Business Insights source Business Insights Niche Blockbuster Orphan Ultra orphan Target Drug Lipitor Erbitux Diacomit Replagal Hyperchole-‐ Colorectal Fabry’s IndicaBon SMEI sterolemia cancer disease Number of 1 million + 100,000 10,000 5,000

Slide 33: Retrophin: Mkt Cap US$372m
Retrophin: Mkt Cap US$372m (1 June 2014) • Clinical program for sub-‐set of chronic kidney disease (focal segmental glomerulosclerosis – an orphan indicaBon) plus some pre-‐clinical compounds. • Lead program RE-‐021 has a dual antagonist for GPCR receptors -‐ angiotensin receptor (AT1T2) blocker
Source: Internet Archive copy of dimerix.com
More decks from Dimerix Limited
Technical Presentation (October 2026)17 slides · Oct 23, 2026
Canaccord Genuity Drug and Device Conference 202635 slides · Oct 12, 2026
ASX SMIDcaps Conference 202616 slides · Sep 23, 2026
E&P Healthcare Conference 202622 slides · Sep 16, 2026
Investor Presentation (September 2026)35 slides · Sep 7, 2026
TechKnow Invest Roadshow (July 2026)16 slides · July 2026